Low Antibody Response Seen With RA Drug (CME/CE)

(MedPage Today) -- Few rheumatoid arthritis patients treated with abatacept (Orencia) developed immunogenic responses that could interfere with efficacy and safety of the biologic agent, an international study found.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news

Related Links:

Conclusions: Both MSCs-derived MPs and Exos exerted an anti-inflammatory role on T and B lymphocytes independently of MSCs priming. However, Exos were more efficient in suppressing inflammation in vivo. Our work is the first demonstration of the therapeutic potential of MSCs-derived EVs in inflammatory arthritis.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
What benefits might tofacitinib offer rheumatoid arthritis patients? How does it compare to other treatment options?Arthritis Research &Therapy
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Menopause may be associated with accelerated functional decline among women with rheumatoid arthritis, a new study suggests.Rheumatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
This study not only offered a novel method for RA therapy but also a guideline for RA targeted drug carrier design. Graphical abstract
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Startup SetPoint Medical has demonstrated “significant, sustained improvement” over two years in a first-in-human study using bioelectronic therapy in patients with rheumatoid arthritis (RA). Seventeen subjects with moderate to severe symptoms were implanted with a vagus nerve stimulator in the European study. At three months, the therapy was shown to have significantly reduced RA symptoms and inhibited cytokine production, according to the company. After 24 months, 87% reported had clinically meaningful responses by standard Annual European Congress of Rheumatology (EULAR) criteria. The Santa Clarita, CA compa...
Source: Mass Device - Category: Medical Devices Authors: Tags: Bioelectronic Medicine Blog Neuromodulation/Neurostimulation Regulatory/Compliance Research & Development rheumatoid arthritis SetPoint Medical vagus nerve stimulation Source Type: news
Conditions:   Rheumatoid Arthritis;   Rheumatoid Arthritis of Foot (Disorder) Interventions:   Device: Foot orthotics;   Device: Standard insole Sponsors:   Vendsyssel Hospital;   TrygFonden, Denmark;   The Danish Rheumatism Association;   Aalborg University;   King Christian X´Hospital for Rheumatic Diseases Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Patients with rheumatic diseases are being increasingly asked to participate in treatment decisions with their physicians. This is especially true for clinical scenarios in which multiple options exist, such as escalating care to treat-to-target in rheumatoid arthritis. In order to effectively participate in medical decisions, patients must be able to differentiate between competing risks. While informed decision making does not require patients to be able to recall specific verbatim numeric information, it does require patients to be able to distinguish between a rare and very rare (e.g., 1% versus a 0.1%) probability of ...
Source: Patient Education and Counseling - Category: International Medicine & Public Health Authors: Source Type: research
Conclusions This study is the first to examine associations of long-chain n-3 polyunsaturated fatty acids intake with OA risk and the largest to examine associations with RA risk. Despite their therapeutic potential, the study provides no evidence of benefit of these nutrients in relation to arthritis risk.
Source: Journal of the Academy of Nutrition and Dietetics - Category: Nutrition Source Type: research
Publication date: Available online 18 June 2018 Source:The Lancet Author(s): Mark C Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert-Roth, Ying Zhang, Yijie Zhou, Mohamed-Eslam F Mohamed, Sebastian Meerwein, Aileen L Pangan Background Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate response to biologic disease-modifying anti-rheumatic drugs (bDMARDs). Methods We did this ...
Source: The Lancet - Category: General Medicine Source Type: research
This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide. Using interactive response technology, we randomly assigned patients receiving stable background csDMARDs (2:2:1:1) to receive a once-daily extended-release formulation of upadacitinib 15 mg or 30 mg, or placebo, for ...
Source: The Lancet - Category: General Medicine Source Type: research
More News: Abatacept | Arthritis | Geriatrics | Orencia | Rheumatoid Arthritis | Rheumatology | Study